RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 88 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.28 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,712,435 | +120.1% | 406,662 | +154.4% | 0.02% | +142.9% |
| Q4 2022 | $1,232,312 | +3.8% | 159,833 | +43.3% | 0.01% | 0.0% |
| Q3 2022 | $1,187,000 | +521.5% | 111,575 | +376.7% | 0.01% | +600.0% |
| Q2 2022 | $191,000 | -69.9% | 23,408 | -73.6% | 0.00% | -80.0% |
| Q1 2022 | $635,000 | +9.7% | 88,748 | +162.7% | 0.01% | -16.7% |
| Q4 2021 | $579,000 | -9.1% | 33,777 | +22.0% | 0.01% | -25.0% |
| Q3 2021 | $637,000 | +28.4% | 27,686 | +103.6% | 0.01% | +33.3% |
| Q2 2021 | $496,000 | – | 13,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |